THE TICK-BORNE ENCEPHALITIS VIRUS (TBEV)

Clinical trials for THE TICK-BORNE ENCEPHALITIS VIRUS (TBEV) explained in plain language.

Never miss a new study

Get alerted when new THE TICK-BORNE ENCEPHALITIS VIRUS (TBEV) trials appear

Sign up with your email to follow new studies for THE TICK-BORNE ENCEPHALITIS VIRUS (TBEV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New antibody shot against tick virus heads to first human tests

Disease control Not yet recruiting

This early-stage study tests a new antibody drug called TBE025 in 18 healthy adults aged 18 to 55. The goal is to see if it is safe and how the body processes it when given through a vein. Participants get a single dose and are closely monitored for side effects. This research he…

Matched conditions: THE TICK-BORNE ENCEPHALITIS VIRUS (TBEV)

Phase: PHASE1 • Sponsor: Giuseppe Pantaleo • Aim: Disease control

Last updated Apr 30, 2026 15:52 UTC

THE TICK-BORNE ENCEPHALITIS VIRUS (TBEV)

Get alerted when new THE TICK-BORNE ENCEPHALITIS VIRUS (TBEV) trials appear

New antibody shot against tick virus heads to first human tests